HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NMTC
NeuroOne Medical Technologies Corporation
NMTC lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NMTC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
NMTC's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NMTC PE Valuation
NMTC has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NMTC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
NMTC has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NMTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.04 | -$0.14 |
| Q1 2026 | -$0.94 | +$0.38 |
| Q4 2025 | -$1.08 | +$0.48 |
| Q3 2025 | -$0.54 | +$2.22 |
| Q2 2025 | -$0.90 | +$1.98 |
| Q1 2025 | -$1.32 | +$2.16 |
| Q4 2024 | -$1.56 | +$2.52 |
| Q3 2024 | -$2.76 | +$1.14 |
NMTC has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NMTC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over NMTC on profitability, with a higher operating margin.
NMTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2M | +16% |
| Q1 2026 | $1.9M | +34% |
| Q4 2025 | $2.9M | -12% |
| Q3 2025 | $2.7M | +907% |
| Q2 2025 | $1.7M | +105% |
| Q1 2025 | $1.4M | +0.7% |
| Q4 2024 | $3.3M | +235% |
| Q3 2024 | $272.3K | -63% |
NMTC's revenue is recovering but still below its 2024 peak: $2M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -123% | -12 points |
| Q1 2026 | -129% | +65 points |
| Q4 2025 | -59% | -111 points |
| Q3 2025 | -50% | +985 points |
| Q2 2025 | -111% | +227 points |
| Q1 2025 | -193% | +16 points |
| Q4 2024 | 52% | +399 points |
| Q3 2024 | -1034% | -608 points |
NMTC's operating margin was −123% last quarter, down 12 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
NMTC has the stronger cash trend. Its trailing FCF is up 8.9% versus its history, compared with HIMS at down 84%.
NMTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$1.4M | -$1.3M |
| Q4 2025 | -$3.2M | -1617% |
| Q3 2025 | -$1.5M | +$1.2M |
| Q1 2025 | -$56.1K | +$2.2M |
| Q4 2024 | $208K | +$4.1M |
| Q3 2024 | -$2.7M | +$256.7K |
| Q2 2024 | -$2.4M | +$704.3K |
| Q1 2024 | -$2.2M | +$1.5M |
NMTC has burned cash in almost every quarter: −$7M over the past year, against −$5M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NMTC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NMTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +255K shares |
| 1 year | +69% | +3.6M shares |
| 3 years | +223% | +6M shares |
| 5 years | +868% | +7.8M shares |
| Available history | +1227% | +8.1M shares |
NMTC has 9M diluted shares, up 69% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NMTC Net Leverage
NMTC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NMTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.9 | Oversold |
| Stochastic | 3.3 | Oversold |
NMTC's weekly RSI is 22 (oversold) and its Stochastic is 3 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NMTC PE vs Healthcare Sector
NMTC has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NMTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.00 | 25% below |
| 20 week MA | $1.59 | 53% below |
| 50 week MA | $3.28 | 77% below |
| 100 week MA | $4.09 | 82% below |
| 200 week MA | $5.51 | 86% below |
NMTC is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over NMTC on returns for 2026, with the stronger performance.
NMTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.7 | $27.5 | -32% |
| 2021 | $27.5 | $13.2 | -52% |
| 2022 | $13.2 | $9.24 | -30% |
| 2023 | $9.24 | $9.48 | +2.6% |
| 2024 | $9.48 | $4.91 | -48% |
| 2025 | $4.91 | $4.38 | -11% |
| 2026 YTD | $4.38 | $0.75 | -83% |
NMTC has finished lower in five of the last six years. It's down 83% so far in 2026.